Cullinan Therapeutics, Inc.
NASDAQ:CGEMMedical - Pharmaceuticals
+$0.62 today
- Market cap
- $584.94M
- Beta
- 0.01
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$3.73
Volume 1.06M
Average 0.99M
CGEM Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Cullinan Therapeutics, Inc.NASDAQ: CGEM
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses dips below year-ago levels
Q1 FY2026 operating expenses of $53.7M fell 2.4% year over year, behind the +15.1% change in trailing-twelve-month operating expenses. Sequentially, it fell 2.8% from the prior quarter.
Context
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -2.4% toward the trailing-twelve-month pace of +15.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 241.65M USD
- Year-over-year change
- +22.9%
- 4-year CAGR
- +29.1%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 241.65M | +22.9% |
| FY2024 | 2024-12-31 | 196.61M | +2.9% |
| FY2023 | 2023-12-31 | 191.09M | +232.1% |
| FY2022 | 2022-12-31 | (144.65M) | -266.5% |
| FY2021 | 2021-12-31 | 86.9M | — |
Operating Expenses vs competitors
How CGEM compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +15.1% is the 4th highest of 11, against a peer median of +5.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $740.02M USD | -0.1% | +14.3% | 54.5% | |
| LTM Aug 2026 | $317.52M USD | +142.5% | +109.8% | 45.2% | |
| LTM Jun 2026 | $261.54M USD | +14.7% | +83.3% | 249.1% | |
| LTM Mar 2026 | €250M EUR | +22.1% | +17.2% | 670.3% | |
| LTM Mar 2026 | $240.35M USD | +15.1% | — | — | |
| LTM Mar 2026 | $190.31M USD | -2.8% | -18.0% | 240.4% | |
| LTM Mar 2026 | $173.51M USD | -10.6% | -12.1% | 110.5% | |
| LTM Mar 2026 | $168.69M USD | +127.4% | +30.3% | 780.5% | |
| LTM Mar 2026 | $156.87M USD | +11.7% | +68.8% | — | |
| LTM Mar 2026 | $91.02M USD | -33.2% | -6.5% | — | |
| LTM Mar 2026 | $33.28M USD | -2.6% | -8.4% | 45.8% | |
| Peer median (excluding CGEM) | — | +5.8% | +15.8% | 175.4% | |
Competitors are the stored peer set for CGEM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 18.94M | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 306K | 0 |
| Gross Profit | 18.94M | 0 | 0 | (306K) | 0 |
| Gross Margin | 100.0% | — | — | — | — |
| Research & Development | 57.75M | 91.95M | 148.16M | 142.9M | 187.4M |
| Selling, General & Admin | 29.15M | 40.19M | 42.49M | 53.71M | 54.25M |
| Operating Expenses | 86.9M | (144.65M) | 191.09M | 196.61M | 241.65M |
| Depreciation & Amortization | 53K | 93K | 310K | 306K | 311K |
| EBITDA | (67.43M) | (132.04M) | (190.34M) | (167.15M) | (219.57M) |
| EBITDA Margin | -356.0% | — | — | — | — |
| Operating Income | (67.95M) | 144.65M | (191.09M) | (196.92M) | (241.65M) |
| Operating Margin | -358.7% | — | — | — | — |
| Interest Income | 477K | 6.61M | 21.63M | 29.66M | 22.21M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 469K | 6.67M | 21.87M | 29.46M | 21.77M |
| Income Before Tax | (67.49M) | 151.32M | (169.22M) | (167.46M) | (219.88M) |
| Pre-Tax Margin | -356.3% | — | — | — | — |
| Income Tax Expense | 0 | 42.12M | (14.12M) | 117K | 0 |
| Net Income | (65.57M) | 111.21M | (153.16M) | (167.38M) | (219.88M) |
| Net Margin | -346.1% | — | — | — | — |
| EPS (Basic) | (1.48) | 2.46 | (3.69) | (3.11) | (3.72) |
| EPS (Diluted) | (1.48) | 2.38 | (3.69) | (3.11) | (3.72) |
| Weighted Avg Shares | 44.29M | 45.16M | 41.51M | 53.77M | 59.05M |
| Weighted Avg Shares (Diluted) | 44.29M | 46.64M | 41.55M | 53.77M | 59.05M |
Cullinan Therapeutics, Inc.
NASDAQ:CGEM
Intrinsic Alpha fair value
Locked
Current Price
$9.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.